<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133835</url>
  </required_header>
  <id_info>
    <org_study_id>97.187</org_study_id>
    <nct_id>NCT00133835</nct_id>
  </id_info>
  <brief_title>Comparison of Extracorporeal Shock Wave Lithotripsy (ESWL) Alone and ESWL Plus Endoscopy for Painful Chronic Pancreatitis</brief_title>
  <official_title>Comparison of ESWL Alone and ESWL Combined With Endoscopic Drainage of the Main Pancreatic Duct for Painful Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasme University Hospital</source>
  <brief_summary>
    <textblock>
      Endoscopy is an established method of treatment for painful obstructive calcified&#xD;
      pancreatitis. It involves the disintegration of calcifications using extracorporeal shock&#xD;
      wave lithotripsy (ESWL) followed by endoscopic removal of stone fragments possibly associated&#xD;
      with stent insertion. A pilot study suggests that ESWL alone relieves pain in calcified&#xD;
      chronic pancreatitis (CP). The aim of this study is to compare both techniques in a&#xD;
      randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic drainage of the main pancreatic duct is an established method of treatment of&#xD;
      painful obstructive calcified chronic pancreatitis (CP). It involves disintegration of&#xD;
      calcifications using extracorporeal shock wave lithotripsy (ESWL) followed by endoscopic&#xD;
      removal of stone fragments, possibly associated with stent insertion. A pilot study suggests&#xD;
      that ESWL alone in calcified CP is followed by spontaneous elimination of stone fragments and&#xD;
      pain relief, without sphincterotomy. After ESWL alone, the exocrine function was found to&#xD;
      return to normal values in some cases. Potential benefits include lower costs and morbidity&#xD;
      as well as wider availability compared to endoscopic techniques.&#xD;
&#xD;
      The primary outcome of this randomized controlled trial is to compare the relapse of pain at&#xD;
      2 years after treatment with ESWL alone or endoscopic treatment, consisting of ESWL followed&#xD;
      by endoscopic stone extraction. Secondary outcomes include a comparison of technical results&#xD;
      (as assessed by abdominal CT Scan 1 week after the last intervention and secretin-enhanced&#xD;
      magnetic resonance at 1 month), complication rates, and treatment-related costs in both&#xD;
      groups.&#xD;
&#xD;
      Patients are eligible to participate in the study according to the following criteria:&#xD;
&#xD;
      Inclusion criteria :&#xD;
&#xD;
        -  painful chronic pancreatitis (abdominal pain attack during the preceding 12 months);&#xD;
&#xD;
        -  at least 1 calcified stone greater than 4 mm in one of its axes in the cephalic or&#xD;
           corporeal portion of the main pancreatic duct with upstream duct dilation;&#xD;
&#xD;
        -  written informed consent obtained from the patient.&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  history of treatment of the pancreas using ESWL, endoscopy, or surgery;&#xD;
&#xD;
        -  pancreatic collection greater than 2 cm in diameter at magnetic resonance or CT Scan;&#xD;
&#xD;
        -  alkaline phosphatase levels greater than twice the upper limit of normal values or signs&#xD;
           of cholangitis;&#xD;
&#xD;
        -  age below 18 years;&#xD;
&#xD;
        -  pregnancy or lactation.&#xD;
&#xD;
      Pretherapeutic work-up will include detailed medical history (including date of the first&#xD;
      episode of typical abdominal pain, date of diagnosis of CP, number of episodes of pain during&#xD;
      the last year, alcohol intake, pain continuous or intermittent during the last episode,&#xD;
      medication, intensity of the last episode of pain on a 10-point scale as previously&#xD;
      described), blood chemistry, stool sampling (for elastase measurement), triolein breath test,&#xD;
      plain abdominal film taken in four classical positions (left anterior oblique, right anterior&#xD;
      oblique, lateral, and supine), CT Scan without contrast medium injection, and&#xD;
      secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP).&#xD;
&#xD;
      After informed consent of the referring physician has been obtained, patients will be asked&#xD;
      to participate in the study. If the patient accepts, after oral and written consent, he (or&#xD;
      she) will be randomized to the ESWL or endoscopy group by opening an opaque sealed envelope&#xD;
      numbered according to a table of random numbers.&#xD;
&#xD;
      ESWL will be performed in all patients using a electromagnetic lithotriptor as previously&#xD;
      described. Shock-waves will be focused on the obstructing stones (if multiple stones are&#xD;
      present, those responsible for MPD obstruction will be identified by comparing plain&#xD;
      abdominal film, CT Scan and S-MRCP). ESWL sessions will be repeated if necessary, until stone&#xD;
      fragmentation is obtained, as confirmed by abdominal plain film centered on the targeted area&#xD;
      of the pancreas. At this time, treatment will be considered terminated in the ESWL group,&#xD;
      patients in the endoscopy group will undergo endoscopy immediately, for endoscopic extraction&#xD;
      of stone fragments possibly associated to stent insertion according to previously published&#xD;
      criteria and techniques.&#xD;
&#xD;
      Cross-over: in the ESWL group, if no elimination of the fragments is observed one week after&#xD;
      the last ESWL, endoscopic drainage of the main pancreatic duct will be carried out at this&#xD;
      time in case of continuous pain. For patients without continuous pain, delayed spontaneous&#xD;
      elimination of the fragments will be sought by CT Scan and S-MRCP 2 months after the last&#xD;
      ESWL. Endoscopic drainage of the main pancreatic duct will be proposed during follow-up only&#xD;
      to the patients presenting a painful attack of CP.&#xD;
&#xD;
      Follow-up will consist of clinical examination 1 month after treatment and every 6 months&#xD;
      thereafter. Data collected will include pain relapses, ESWL, endoscopic and surgical&#xD;
      procedures, weight change, plus any other seemingly unrelated medical treatments. In addition&#xD;
      to this, a S-MRCP will be performed 1 month after treatment. Triolein breath test will be&#xD;
      performed at 1 month and 1 year. Sampling of stools (for elastase measurement) will be&#xD;
      obtained every year.&#xD;
&#xD;
      Costs will be calculated starting on the day of first treatment as previously described.&#xD;
      Costs not directly related to the treatment of pain or of procedure-related complications&#xD;
      (e.g., diabetes) will be disregarded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1998</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse of pain at 2 years</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diameter of the main pancreatic duct at 1 month</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate at 1 month</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related costs of initial intervention and during follow-up</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Pancreatitis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal shock wave lithotripsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic drainage of the main pancreatic duct</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Painful chronic pancreatitis (&gt;1 abdominal pain attack during the preceding 12 months)&#xD;
&#xD;
          -  At least 1 calcified stone greater than 4 mm in one of its axes in the cephalic or&#xD;
             corporeal portion of the main pancreatic duct (MPD) with upstream duct dilation&#xD;
&#xD;
          -  Written informed consent obtained from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of treatment of the pancreas using ESWL, endoscopy, or surgery&#xD;
&#xD;
          -  Pancreatic collection greater than 2 cm in diameter at magnetic resonance or CT scan&#xD;
&#xD;
          -  Alkaline phosphatase levels greater than twice the upper limit of normal values or&#xD;
             signs of cholangitis&#xD;
&#xD;
          -  Age below 18 years&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Marc Dumonceau</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacques Devi√®re</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasme University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guido Costamagna</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of Roma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology and Hepatopancretology; Erasme University Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Endoscopy Unit, Department of Surgery, Catholic University</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2005</verification_date>
  <study_first_submitted>August 22, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2005</study_first_posted>
  <last_update_submitted>October 24, 2005</last_update_submitted>
  <last_update_submitted_qc>October 24, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2005</last_update_posted>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Lithotripsy</keyword>
  <keyword>Cholangiopancreatography, Endoscopic Retrograde</keyword>
  <keyword>Abdominal pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

